As Figure 4 shows, in SOT recipients and controls with previous infection, modeled anti-RBD IgA GMCs were 2.7 (95% CI: 1.6-5.6) AU/mL and 2.9 (95% CI: 1.7-6.0) AU/mL (p=0.377) at baseline while modeled anti-RBD IgA GMCs were 390 (95% CI: 230-628) and 375 (95% CI: 256-532) (p=0.597) 12 months after first vaccine dose. This evidence concerns the gene CD79A and infection.